Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Infused SNB-101(as SN-38) in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase I, Open-Label, Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Infused SNB-101(as SN-38) in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SNB 101 (Primary) ; Irinotecan
  • Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors SN BioScience

    • Most Recent Events

    • 29 Feb 2024 According to a SN BioScience media release,SNB-101 been approved for phase 1 clinical trials in the US (NCT04640480) and Korea,
    • 22 Nov 2023 Planned End Date changed from 31 Dec 2023 to 30 Jun 2025.
    • 22 Nov 2023 Planned primary completion date changed from 31 May 2023 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top